The corrections required are as follows Correction 1
In the Methods section under the heading "Vaccine effectiveness", the sentence:
"The protection effectiveness of Rotarix and Rotateq were derived from randomized controlled trials in other Asian regions such as Hong Kong, Taiwan and Singapore, considering the ethnic homogeneity [25], because there was no eligible data specifically for the Chinese population." has been corrected to: "The protection effectiveness of Rotarix and Rotateq were derived from randomized controlled trials [25] and clinical reviews cited by economic evaluation studies in other Asian regions such as Hong Kong, Taiwan and Singapore, due to no eligible data specifically for the Chinese population."
Correction 2
In the Results section under the heading "Health impacts and cost-effectiveness of vaccination", the sentence:
"The total cost is even less than non-vaccination." has been corrected to: "The ACER is even less than non-vaccination."
Correction 3
Four corrections are required to Table 1 as follows: Rotateq efficacy: the plausible range for sensitivity analysis "0 -0.98" has been corrected to "0.883 -1"; Source "38" has been corrected to "38, 42".
"Mortality rate" under the heading "Parameters" has been removed as it appeared twice in the Table. Costs for international vaccinations: the plausible range for sensitivity analysis "5 -250" has been corrected to "50 -250" Infection rate: Source: "34" has been corrected to "21, 45". A corrected version of Table 1 appears below.
Correction 4
The values presented in Table 2 were mislabelled and incorrectly shown. The correct version of Table 2 is shown below.
Correction 5
The axes in Figure 2 were mislabelled. The correct version of Figure 2 is shown below.
Correction 6
The following reference should be included in the refer- 
